{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361418520235332736.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/s0272-6386(97)90459-5"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0272638697904595?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0272638697904595?httpAccept=text/plain"}},{"identifier":{"@type":"NAID","@value":"30035791037"}}],"dc:title":[{"@value":"Hyperparathyroidism in the hemodialysis population: A survey of 612 patients"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381418520235332736","@type":"Researcher","foaf:name":[{"@value":"Mahmoud M. Salem"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02726386"}],"prism:publicationName":[{"@value":"American Journal of Kidney Diseases"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"1997-06","prism:volume":"29","prism:number":"6","prism:startingPage":"862","prism:endingPage":"865"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0272638697904595?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0272638697904595?httpAccept=text/plain"}],"createdAt":"2008-03-18","modifiedAt":"2025-10-03","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1390004222630339968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679656701056","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Management of calcium by oral vitamin D analogs during calcimimetics therapy for secondary hyperparathyroidism"},{"@language":"ja","@value":"二次性副甲状腺機能亢進症に対するシナカルセト治療―経口ビタミンＤ製剤併用による血清カルシウム調節―"},{"@language":"ja-Kana","@value":"2ジセイ フクコウジョウセン キノウ コウシンショウ ニ タイスル シナカルセト チリョウ ケイコウ ビタミン D セイザイ ヘイヨウ ニ ヨル ケッセイ カルシウム チョウセツ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679657467776","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The effects of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients with citrate dialysate"},{"@language":"ja","@value":"塩酸セベラマー内服量が血液透析患者の酸塩基平衡に及ぼす影響―クエン酸透析液使用でも，代謝性アシドーシスを悪化させるか？―"},{"@language":"ja-Kana","@value":"エンサン セベラマー ナイフクリョウ ガ ケツエキ トウセキ カンジャ ノ サンエンキ ヘイコウ ニ オヨボス エイキョウ クエンサン トウセキエキ シヨウ デモ タイシャセイ アシドーシス オ アッカ サセル カ"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950399206548352","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Potential factors regulating serum parathyroid hormone in maintenance hemodialysis patients: 4-year retrospective study"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s0272-6386(97)90459-5"},{"@type":"CIA","@value":"30035791037"},{"@type":"CROSSREF","@value":"10.4009/jsdt.42.857_references_DOI_HjEJYazwi7ZOqNr95TMbXyskMsw"},{"@type":"CROSSREF","@value":"10.4009/jsdt.43.373_references_DOI_HjEJYazwi7ZOqNr95TMbXyskMsw"},{"@type":"CROSSREF","@value":"10.1248/bpb.b20-00472_references_DOI_HjEJYazwi7ZOqNr95TMbXyskMsw"}]}